ViiV Healthcare
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, ViiV Healthcare sits in the top decile of US sponsors by registered trial count (#165 of 15,742 sponsors by registered trial count).
ViiV Healthcare: 182 sponsored US clinical trials, 7 recruiting.
ViiV Healthcare sponsors 182 registered US clinical trials on ClinicalTrials.gov, 7 of them currently recruiting, and 147 completed. 47 of these trials are in Phase 3-4 (later-stage) and 132 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 36 trials.
Top-decile sponsor footprint
ViiV Healthcare ranks in the top decile of sponsors by registered trial count (#165 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
147 of 163 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
182 total, page 3 of 4
Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers
NCT02185300
Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529
NCT02164045
Drug-drug Interaction (DDI) Rifabutin
NCT02138084
A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects
NCT02120352
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
NCT02105987
Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)
NCT02076178
Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects
NCT02082808
A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects
NCT02059031
Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects
NCT02064374
Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction
NCT02027454
Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects
NCT01967771
A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)
NCT01910402
An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects
NCT01848340
A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects
NCT01754116
Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine
NCT01641809
Relative Bioavailability Study of GSK1265744 Formulations
NCT01648257
Dolutegravir Expanded Access Study
NCT01536873
Evaluation of the Bioequivalence of a Combined Formulated Tablet
NCT01622790
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects
NCT01593046
Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir
NCT01568892
A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).
NCT01563328
A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects
NCT01499199
Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol
NCT01498861
A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects
NCT01467531
Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects
NCT01449929
Drug Interaction Study Between Dolutegravir and Prednisone
NCT01425099
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1
NCT01345630
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
NCT01384734
Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets
NCT01366547
Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir
NCT01382238
Dolutegravir Renal Impairment Study
NCT01353716
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
NCT01327547
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
NCT01328041
Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers
NCT01231542
A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese Subjects
NCT01332565
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
NCT01263015
GSK1349572 Hepatic Impairment Study
NCT01231529
A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults
NCT01231516
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
NCT01227824
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection
NCT01199731
A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects
NCT01214993
A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.
NCT01195974
A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435
NCT01209117
GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir
NCT01209065
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
NCT01102972
A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects
NCT01101893
GSK1349572 Relative Bioavailability Study
NCT01098513
GSK1349572 Drug Interaction Study With Efavirenz
NCT01098526
Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers
NCT01068925
A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761
NCT01031472
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 98 |
| Phase 2 | 34 |
| Phase 3 | 39 |
| Phase 4 | 8 |
What is open in the ViiV Healthcare pipeline
7 recruiting of 182 indexed (4% open); 147 completed (81%).
Phase mix: 47 late (III/IV) vs 132 early (I/II) (early-phase heavy).
Top condition: HIV Infections (36 trials), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
ViiV Healthcare: open-pipeline peers nationwide
Peers matched on 182 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
ViiV Healthcare sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 182 trials (± recruiting share)
- Fox Chase Cancer Center · 183 trials · 16% recruiting
- Abbott · 181 trials · 0% recruiting
- Children's Mercy Hospital Kansas City · 184 trials · 11% recruiting
- Baylor Research Institute · 180 trials · 17% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Aldeyra Therapeutics · 4% recruiting · 26 trials
- DexCom · 4% recruiting · 26 trials
- MaineHealth · 4% recruiting · 26 trials
- Medtronic Spinal and Biologics · 4% recruiting · 26 trials
Related
What to do with this ViiV Healthcare page
182 registered trials is a research-attention snapshot, not an endorsement of ViiV Healthcare or any single study.
- 7 of ViiV Healthcare's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition ViiV Healthcare studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. ViiV Healthcare pipeline card: 182 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.